Landos Biopharma, Inc. announced a private placement of 30,909,090 shares at an issue price of $0.54 per share for the gross proceeds of $16,690,908.6 on January 4, 2023. The transaction will include participation from returning investor Perceptive Advisors LLC, largest shareholder in the company. The closing of the financing is subject to customary closing conditions and is expected to close on or before January 10, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.93 USD | +0.58% |
|
-.--% | +526.50% |
13/06 | AbbVie inks immune disorder drug licensing deal with China's FutureGen | RE |
24/05 | Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+526.50% | 71.68M | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- Landos Biopharma, Inc. announced that it expects to receive $16.690909 million in funding from Perceptive Advisors LLC